Biospective is a leading Contract Research Organization (CRO) specializing in Neuroscience research studies. We have extensively validated and readily available rodent models of ALS (TDP-43), Alzheimer's disease (beta-amyloid and tau), Parkinson's disease (alpha-synuclein), and multiple sclerosis (EAE and cuprizone) for preclinical research studies. We offer a wide range of preclinical services to evaluate therapeutic agents in these models, including dosing, motor & sensory function, cognition & sleep, electrophysiology, fluid & cellular biomarkers, in vivo imaging (MRI, CT, PET, SPECT), image processing, image analysis, histology, IHC, multiplex immunofluorescence, and spatial biology analysis.Biospective is also a full-service Neuroimaging Core Lab for clinical trials. Our multidisciplinary team provides a comprehensive spectrum of services, including imaging study operations, central eligibility & safety reads, and quantitative image processing & analysis for early through late phase clinical trials. We are the industry leader in quantitative imaging biomarkers derived from multiple modalities, including MRI, PET, and SPECT, for clinical trials of Alzheimer's disease & tauopathies, Parkinson's disease & MSA, white matter diseases, and genetic & rare diseases.